Abstract
Dementia is a frequent and debilitating complication of Parkinson’s disease (PD). It typically is gradual in onset and occurs after a number of years of disease. Longitudinal studies indicate that up to 80% of PD patients may develop dementia during their disease course, though this figure varies. Cognitive deficits in PD dementia (PDD) affect more than one cognitive domain, such as attention, working memory, executive function, memory, language, and/or visuospatial functions and are severe enough to impair daily life, independent of motor symptoms. Behavioral symptoms such as depression, apathy, psychosis, and excessive daytime sleepiness can accompany PDD. To date, rivastigmine is the only FDA-approved medication for PDD. There is growing interest in other pharmacological and non-pharmacological treatments for PDD including medications, neuromodulation, and physical and cognitive exercise. Management strategies include avoiding medications that can exacerbate cognitive impairment (such as anticholinergics); treating comorbid neuropsychiatric symptoms; addressing driving, safety, and/or work issues; and providing support to the patient and care partner.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Suggested Reading
Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613–8.
Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, et al. Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007;22(16):2314–24.
Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G, et al. Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord. 2012;27(10):1230–8.
Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351(24):2509–18.
Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007;22:1689–707.
Emre M, Tsolaki M, Bonuccelli U, Destee A, Tolosa E, Kutzelnigg A, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969–77.
Goldman JG, Holden S. Treatment of psychosis and dementia in Parkinson’s disease. Curr Treat Options Neurol. 2014;16:281.
Goldman JG, Weintraub D. Advances in the treatment of cognitive impairment in Parkinson’s disease. Mov Disord. 2015;30(11):1471–89.
Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23:837–44.
Kulisevsky J, Pagonabarraga J. Cognitive impairment in Parkinson’s disease: tools for diagnosis and assessment. Mov Disord. 2009;24:1103–10.
Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner Fisman G, Anderson K, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:996–1002.
Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the nonmotor symptoms of Parkinson’s disease. Mov Disord. 2011;26(Suppl 3):S42–80.
Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population based cohort. J Neurol Neurosurg Psychiatry. 2013;84:1258–64.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Goldman, J.G. (2019). Treatment of Dementia in Parkinson’s Disease. In: Reich, S., Factor, S. (eds) Therapy of Movement Disorders. Current Clinical Neurology. Humana, Cham. https://doi.org/10.1007/978-3-319-97897-0_24
Download citation
DOI: https://doi.org/10.1007/978-3-319-97897-0_24
Published:
Publisher Name: Humana, Cham
Print ISBN: 978-3-319-97896-3
Online ISBN: 978-3-319-97897-0
eBook Packages: MedicineMedicine (R0)